NewEdge Advisors’s PDS Biotechnology PDSB Stock Holding History

NewEdge Advisors’s Portfolio PDSB Stock Details PDSB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-427	Closed	-$2.15K	–	3599
2023 Q2	$2.15K	Buy	+427	New	+$2.8K	﹤0.01%	3071

Other funds holding PDSB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

IWA

Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

NewEdge Advisors's PDSB Position: Q3 2023 in Review

NewEdge Advisors sold out of PDS Biotechnology (PDSB) in Q3 2023, closing a stake of 427 shares — an estimated $2.15K sold.

NewEdge Advisors first reported a position in PDSB in Q2 2023 and held it in 1 quarter. The position peaked at $2.15K in Q2 2023. 78 funds tracked by Wall St. Rank hold PDSB as of Q3 2023.

NewEdge Advisors reported no remaining PDS Biotechnology position as of Q3 2023 after selling out during the quarter.
NewEdge Advisors sold 427 PDS Biotechnology shares in Q3 2023, an estimated $2.15K.
NewEdge Advisors first reported a position in PDS Biotechnology in Q2 2023 and held it in 1 quarter.
NewEdge Advisors's PDS Biotechnology position peaked at $2.15K in Q2 2023.
78 funds tracked by Wall St. Rank held PDS Biotechnology as of Q3 2023.

Based on NewEdge Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.